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a b s t r a c t
Free radicals originate from both exogenous environmental sources and as by-products of the respiratory
chain and cellular oxygen metabolism. Sustained accumulation of free radicals, beyond a physiological
level, induces oxidative stress that is harmful for the cellular homeodynamics as it promotes the
oxidative damage and stochastic modiﬁcation of all cellular biomolecules including proteins. In relation
to proteome stability and maintenance, the increased concentration of oxidants disrupts the functionality
of cellular protein machines resulting eventually in proteotoxic stress and the deregulation of the
proteostasis (homeostasis of the proteome) network (PN). PN curates the proteome in the various cellular
compartments and the extracellular milieu by modulating protein synthesis and protein machines
assembly, protein recycling and stress responses, as well as refolding or degradation of damaged
proteins. Molecular chaperones are key players of the PN since they facilitate folding of nascent
polypeptides, as well as holding, folding, and/or degradation of unfolded, misfolded, or non-native
proteins. Therefore, the expression and the activity of the molecular chaperones are tightly regulated at
both the transcriptional and post-translational level at organismal states of increased oxidative and,
consequently, proteotoxic stress, including ageing and various age-related diseases (e.g. degenerative
diseases and cancer). In the current review we present a synopsis of the various classes of intra- and
extracellular chaperones, the effects of oxidants on cellular homeodynamics and diseases and the redox
regulation of chaperones.
& 2014 The Authors. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Cellular respiratory chain is the most important redox reaction
where reactive oxygen species are produced. During the spatially
and temporally separated series of redox reactions and electrons
which are transferred from one molecule donor to an acceptor
molecule of the electron transport chain in mitochondria, a small
percentage of electrons do not complete the cycle and instead leak
directly to oxygen [1]. Excessive amounts of free radicals and
radical-derived reactive species may also arise from the activity of
NAD(P)H oxidases (NOx) and/or xanthine oxidase, as well as from
nitric oxide synthase (NOS), P450 metabolism and peroxisomes.
Typical products of redox signalling are oxygen free radicals
known as reactive oxygen species (ROS) and reactive nitrogen
species (RNS). Free radicals and their derivatives are highly
reactive and (among others) are comprised of superoxide anion
(O2 ), hydroxyl radical (OH) and the nitric oxide (NO) radical
[1–3]. Notably, free radicals may also arise from exogenous sources
including various types of radiations (e.g. UV light, X-rays or
gamma rays), atmospheric pollutants and metal-catalyzed reac-
tions [1–3].
Free radicals were originally believed to be harmful, but it has
been realized that in physiological concentrations they serve as
redox messengers, which are essential in the regulation of intra-
cellular signalling and signiﬁcant cellular processes including meta-
bolism, antioxidant defenses and responses to pathogens [1,4].
Nevertheless, sustained increased levels of oxygen free radicals
beyond a physiological threshold that exceed cellular antioxidant
capacity are toxic and introduce oxidative stress that affects all
cellular biomolecules. Antioxidant pathways are then activated to
buffer the excess amount of free radicals and re-establish normal
cellular homeodynamics [5–7].
Proteome is modiﬁed post-translationally by either numerous
highly regulated enzymatic protein modiﬁcations (EPMs) (e.g.
phosphorylation, acetylation, ubiquitination, methylation, etc.) or
by non-enzymatic protein modiﬁcations (NEPMs), which are mostly
stochastic and increase with ageing or in age-related diseases
(Fig. 1). NEPMs include (among others) protein oxidation and/or
the formation of Advanced Glycation End Products (AGEs) that are
formed mostly by reducing sugars and reactive aldehydes via the
Maillard reaction and the non-enzymatic glycation of free amino
groups [7–9]. EPMs alter the targeted proteins, which however
remain fully functional, while NEPMs may induce protein unfolding
or misfolding resulting in increased proteome instability. Proteins
and protein machines are particularly vulnerable to oxidative stress
as they are among the major target group of ROS. Reportedly, in a
cell under oxidative stress proteins consist 69% of the oxidized
molecules; the remaining 31% accounts for lipids and DNA [10]. Free
radicals-derived protein modiﬁcation can result in either gain- or
loss-of-function due to the protein misfolding or unfolding. Speci-
ﬁcally, oxidized proteins may lose their secondary or tertiary
structure and thus their stability, activity and/or function are
compromised [7,9,11]. Given the fact that proteins and their
macromolecular assemblies (that form protein machines) are vir-
tually the entities that perform all major cellular functions it is not
surprising that cells invest signiﬁcant energetic effort to retain a
fully functional proteome.
Proteome stability and, most importantly functionality, is
achieved by the action of a cellular modular, yet integrated system
which ensures general proteome quality control and it is called the
proteostasis network (PN) [7,12]. The PN curates the basal func-
tionality and homeodynamics of the proteome and responds to
conditions of proteotoxic stress by addressing the triage decision
of fold, hold, or degrade. Speciﬁcally, PN is constituted of several
complex protein machines that under conditions of proteotoxic
stress aim to, ﬁrstly identify, and then, either rescue (if feasible) or
degrade unfolded, misfolded or non-native polypeptides. Addi-
tional integrated modules of the PN can be considered the protein
synthesis module and the regulatory pathways of the cellular stress
(e.g. heat or oxidative) responses which mobilize the proteome
caretakers; mitotic cells can also dilute proteome damage by mitosis
(Fig. 2).
Central to the PN functionality is the armada of the chaperone
machines which function in a coordinated order to prevent protein
aggregation and either refold unfolded proteins or drive them for
degradation through the main proteolytic systems, namely the
ubiquitin proteasome (UPS) or the autophagy lysosome (ALS)
systems [7,12]. Therefore, both the expression and the activity of
the molecular chaperones are tightly regulated at both the
transcriptional and post-translational level under conditions of
Fig. 1. Proteome is modiﬁed post-translationally by either highly regulated enzy-
matic protein modiﬁcations (EPMs) [e.g. phosphorylation (P), acetylation, ubiqui-
tination, etc.] or by non-enzymatic protein modiﬁcations (NEPMs), which are
mostly stochastic and increase with ageing or in age-related diseases. NEPMs
include (among others) protein oxidation and the formation of Advanced Glycation
End Products [AGEs; (A)] that are formed by reducing sugars and reactive
aldehydes via the non-enzymatic glycation of free amino groups (the Maillard
reaction). EPMs modify targeted proteins, which however remain fully functional,
while NEPMs may induce protein unfolding or misfolding resulting in increased
proteome instability.
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increased oxidative and, consequently, proteotoxic stress. In the
current review we present a synopsis of the various classes of
chaperones, their functional implication in proteome stability, as
well as the effects of oxidants on cellular homeodynamics, diseases
and on the regulation of chaperones.
2. Main classes of molecular chaperones
Molecular chaperones [also referred as heat shock proteins
(HSPs)] are families of multidomain proteins that are involved
in protein folding, unfolding and remodelling. In particular, they
assist newly synthesized proteins to reach their native fold;
mediate either assembly of complexes or unfolding and disas-
sembly while protecting them from various types of stress (e.g.
heat and oxidative stress) and protein aggregation [13,14].
To achieve their goal(s) chaperones function in different ways by
co-operating with many different proteins, binding to different
substrates and performing changes in the structure of proteins to
achieve correct folding. Due to their “multitasking” on a wide
range of substrates and the interactions or different conformations
that the chaperone domains undergo in order to achieve correct
protein folding, they are often referred to as molecular machines.
Chaperone machines are in most cases composed of highly
coordinated moving parts (involving displacements and rotations)
which depend on energy input (i.e. cycles of ATP binding and
hydrolysis) for their function and, although they rather have a
broad spectrum of substrates, their speciﬁcity is enough to ensure
proteome stability [14,15].
At the systemic level (i.e. the organism) chaperones curate the
proteome both intracellularly as well as at the extracellular milieu
(i.e. the biological ﬂuids). Given the immense importance of
proteome stability, it is not surprising that intracellular chaper-
ones are found in virtually all subcellular compartments including
the nucleus, the cytosol, the mitochondria and the endoplasmic
reticulum (ER), while during protein synthesis chaperones keep
proteins from misfolding as they are still being translated [16]. The
diverse family of the prominent HSPs is divided into the small heat
shock proteins (sHSPs) that modulate proteome stability in an
ATP-independent fashion (referred also as “holdases”) and to those
that depend on energy consumption (i.e. ATP) for their function-
ality (e.g. members of the Hsp60, Hsp70, Hsp90 family; often
termed as “foldases”) [13,14].
In those organismal states (e.g. ageing or diseases) where
the chaperone network becomes deregulated, the accumulating
non-native, misfolded or unfolded proteins can form (among
others) ﬁbrils, amyloids or large amorphous aggregates [15]. These
aggregates are responsible for many severe diseases like Alzhei-
mer's, Parkinson's, Huntington's and prion disease since their
accumulation becomes toxic and further disrupts the PN introdu-
cing global proteome instability and downstream proteome damage
responses (PDR) [15]. In other diseases characterized by increased
oxidative and proteotoxic stress (e.g. cancer) high expression levels
of the chaperones contribute to tumor cells detoxiﬁcation and
proteome stability thus increasing tumor cells resistance to ther-
apeutic approaches [7]. Considering that most of the aforemen-
tioned pathological states (including ageing) are characterized by
increased oxidative stress which may then promote proteotoxic
stress, it is essential to explore the mechanisms of redox regulation
of chaperones in order to provide new insights on how these
diseases evolve and how to treat them effectively.
2.1. Small heat shock proteins
sHSPs are ATP-independent members of the heat shock protein
family that form high molecular weight oligomers [17,18]. These
chaperones provide high-afﬁnity binding platforms for unfolded
proteins and prevent protein aggregation speciﬁcally during stress
conditions. There are several sHSPs encoded by the human
genome and even though they are a poorly conserved family all
sHSPs have a similar range of low molecular weight (10–40 kDa)
and share a number of structural and functional characteristics
Fig. 2. Main components of the proteostasis network (PN) and of the proteome damage responses (PDR). In the case of proteome damage cells launch a massive response by
activating the PN, which functions by addressing the triage decision fold, hold or degrade. PN is composed of several modules including the protein synthesis machinery, the
UPR of the ER and the armada of the intra- and extra-cellular chaperones, and ﬁnally, a number of proteases, which (among others) detoxify cells from non-repairable
proteins; mitotic cells can also dilute proteome damage by mitosis. Part of PDR can be also considered the stress responses module, which regulates cellular responses to
oxidative and electrophilic stress (e.g. the Nrf2/Keap1 signalling pathway). Molecular chaperones function in all PN modules and they are key players of the PN and PDR since
apart from facilitating folding of nascent polypeptides they are also involved in holding, folding, and/or degradation of unfolded, misfolded and/or non-native proteins during
stressful conditions (e.g. redox imbalance).
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including a conserved α-crystallin domain that is critical for sHSPs
dimerization and function; the capacity to form large oligomers,
the potent induction under conditions of stress and a dynamic
quaternary structure [19,20]. sHSPs are involved in preventing
aggregation of partially misfolded proteins, while they also associ-
ate and modulate the assembly of most major cytoskeletal com-
ponents [21–23]. Upon heat shock, αB-crystallin translocates from
the nuclear speckles to the nucleoplasm, thereby contributing in
the stability of the nuclear proteome [24]. sHSPs are tightly
regulated by EPMs (e.g. phosphorylation) that enable them to
respond upon stress and to perform their chaperone activities
[25,26]. Furthermore, HSP27 and αB-crystallin target damaged or
mutated proteins to UPS for degradation [27,28], while along with
other sHSPs they interact with many cytoskeletal parts to inhibit
aggregation of misfolded proteins [29]. Moreover, HSP22 stimu-
lates autophagy-mediated degradation of protein aggregates in an
eIF2α-dependent manner [30]. sHSPs are overexpressed upon
many different types of stress as they are key components of the
PN and PDR. Speciﬁcally, they have been found overexpressed in
many different diseases including various types of cancer where
they contribute in reducing proteotoxic stress [7]. Because sHSPs
do not depend on ATP for their function they are not typical
druggable targets and thus current efforts aim to inhibit their
function and provide therapeutic tools via the development of
antisense oligonucleotides that suppress their expression; this
approach has been studied in prostate and bladder cancer with
encouraging, so far, results [31,32].
2.2. Heat shock proteins 60, 70 and 90
The HSP60 family of chaperones (or chaperonins) are oligo-
meric proteins categorized in two subfamilies; group I that is
found in bacteria, mitochondria and chloroplasts, and group II,
which is found in the eukaryotic cytosol and in archaea [33].
Group I includes the bacterial chaperonin 60 (GroEL) and
co-chaperonin 10 (GroES), as well as, the chloroplast and mito-
chondrion speciﬁc HSP60 proteins and their co-chaperonins [34].
Chaperonins are well-established protein machines that ensure
correct protein folding by providing an isolation chamber. GroEL,
which is extensively studied, forms a barrel like structure, com-
prised of two tightly close rings that surround open cavities and
constitute a line of continuous hydrophobic surfaces. This open
structure that resembles a “lid” is where non-native polypeptides
with exposed hydrophobic surfaces are captured. Upon ATP-
dependent binding, GroES (a single heptamer ring) which is
recruited by a GroEL ring, closes the “lid” thereby transforming
the open ring into an isolated chamber with a hydrophilic band
[35]. GroEL and GroES act on the substrate and their coordinated
ATP-dependent action results in unfolding of the enclosed mis-
folded protein [36] while the power of this action also forces the
protein away from the hydrophobic sites and at the same time it
retranslocates it inside the GroES-capped hydrophilic chamber for
folding [37]. In this isolated site the unfolded/misfolded protein
cannot misfold further due to the lack of hydrophobic sites or
other proteins for aggregation, and can either remain in this state
or fold properly according to its amino acid sequence. After a step
of slow ATP hydrolysis, the “lid” is re-opened and if the protein is
correctly folded it will be released or it will otherwise be
recaptured by another chaperonin ring [37]. Group II chaperonins
include the eukaryotic cytosolic chaperonin-containing TCP1 (CCT;
also known as TriC) and the archaeal thermosome. CCT is con-
sisted of rings each one having eight subunits, which are encoded
by eight related but distinct genes [38]; CCT is known to bind to
cytoskeletal proteins among other substrates [39].
HSP70s is an abundant heat shock protein family that is found
in all cellular compartments. HSP70 chaperones have a diverse
array of cellular functions but their major role is to ensure correct
folding of newly synthesized proteins and to perform the refolding
of proteins that are misfolded and/or aggregated. This broad
spectrum of cellular functions is achieved through the ampliﬁca-
tion and diversiﬁcation of HSP70 genes and also by specialized
co-chaperones (e.g. HSP40) that support HSP70s function [40].
The HSP70 proteins are consisted of two domains, namely an
amino-terminal ATPase domain and a carboxy-terminal substrate-
binding domain which is comprised of a helical lid segment and a
β-sandwich subdomain; the latter recognizes proteins' hydropho-
bic amino acids [41,42]; notably, the exposure of this patch of
hydrophobic amino acids correlate with a proteins' tendency to
aggregate [43]. When ATP is bound, the HSP70 helical lid is open
and only when ATP hydrolysis takes place the lid can close [44].
ATP hydrolysis is fastened by HSP40, which also interacts with
unfolded peptides and oxidized proteins and mediates HSP70
recruitment to protein substrates. Upon release of the substrate,
peptides that need time for folding will rebind to HSP70 until they
reach their correct folded state and therefore will be prevented
from aggregation [43]. Moreover, HSP70 cooperates with HSP100
ATPases in disaggregating large aggregates; HSP100 disassembly
machines are unfoldases and “disaggregatases”, which deliver
substrates to compartmentalized proteases (e.g. the proteasome)
or disassemble aggregates containing misfolded proteins [45,46].
Proteins that cannot reach their correct folded state after many
cycles of binding to HSP70 might be translocated to the specialized
chaperonin cage-like structure for correct folding. HSP70 also
functions in the nucleus where it is imported upon thermal stress
to facilitate nuclear proteome stability [47]. A direct connection
between HSP70 and the proteolytic systems involves CHIP (Car-
boxyl terminus of HSP70-Interacting Protein) that targets dena-
tured proteins bound to HSP70 (or to HSP90) to proteasome for
degradation [48].
The HSP90 class of ATP-dependent chaperones are ubiquitously
expressed and account for 1–2% of total cellular proteins in non-
stressed normal cells. These chaperones function downstream to
HSP70 and display a wide range of biological roles and many
“client” proteins. HSP90 exists as a homodimer and functions in
the regulation of signalling and cell cycle by binding client
proteins and enabling their interaction with other proteins or
their ligands. Each monomer protein contains an N-terminal
ATPase domain that is also involved in the interaction with co-
chaperones, a central domain that modulates binding of client
proteins and ATP hydrolysis and a C-terminal high afﬁnity dimer-
ization domain [49]. Among the proteins that are substrates of the
HSP90 system are hormone receptors, kinases and oncogenic
proteins [49]. In general, HSP90s are more specialized than other
chaperones and are essential for survival in eukaryotic cells as they
also are capable of binding non-native polypeptides (at the late
stages of their folding) and preventing their aggregation [14].
Speciﬁcally, HSP90 interacts with co-chaperones and co-regula-
tors, many of which use tetratricopeptide repeat (TPR) domains to
dock onto HSP90, and can bind to non-native proteins in order to
prevent their aggregation [50]. The TPR-motif containing protein,
HSC70-HSP90-organizing protein (HOP, also known as STI1) is one of
these co-regulators that provides a direct link between HSP70 and
HSP90, allowing substrate transfer [50–52]; STI1 also translocates to
the nucleus upon DNA damage implying a potential role for this
protein in genotoxic stress and DNA damage responses [53].
2.3. Endoplasmic reticulum and extracellular chaperones
The intracellular proteins of the secretory pathway and those of
the extracellular millieu are synthesized and processed at the
extracellular-like environment of the ER. Here, unfolded or misfolded
non-repairable proteins will be targeted for ER-associated protein
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degradation (ERAD) via ER-attached proteasomes [54]. Misfolded
proteins in the ER are recognized in mammals by the ER-chaperone,
glucose regulated protein of 78 kDa (GRP78/BiP/HSPA5), which binds
to hydrophobic residues in the unfolded part of proteins [55]. GRP78
(the ER homologue of HSP70) is consisted of an ATPase domain, a
peptide-binding domain and a KDEL ER-retention signal [56]. Under
physiological conditions GRP78 is kept at an inert state by binding to
three ER proteins, namely the activating transcription factor-6 (ATF6),
the inositol-requiring transmembrane kinase/endoribonuclease
1 (IRE1) and the double-stranded RNA (PKR)-activated protein
kinase-like eukaryotic initiation factor 2 kinase (PERK) [7,56]. Upon
ER proteotoxic stress, GRP78 dissociates from its binding partners,
which are then free to trigger the Unfolded Protein Response (UPR) by
regulating speciﬁc gene responses aiming to restore ER proteome
stability. The three sensors of ER proteotoxic stress facilitate contra-
dictory responses since they either promote cell survival by decreasing
the misfolded protein and/or oxidative load, or, if UPR fails, they
promote the activation of apoptotic pathways that eventually result in
cell death [57]. Other molecular chaperones of the ER are ERp72,
GRP94, GRP170/ORP150, protein disulﬁde isomerase (PDI), cyclophilin
B, CaBP1 (calcium binding protein) and SDF2- L1 [58].
The extracellular space (that is a continuous with the lumen of ER
and Golgi) faces various challenges in retaining proteostasis as it
virtually lacks ATP [59]; the abundance of intracellular chaperones (e.g.
HSP70) is normally extremely low [60] and it is more oxidized than
the nucleo-cytosolic compartments. Moreover, it is readily affected by
environmental stressors and it is also subject to shear stress due to the
continuous pumping of plasma around the body [61]. A number of
secreted glycoproteins, namely haptoglobin [62], α(2)-Macroglobulin
[α(2)M] [63] and apolipoprotein J/Clusterin (CLU) [64] have been
recently proposed to act as extracellular chaperones, due to their
demonstrated ATP-independent chaperone properties. Moreover, it
was shown that the concentration of the extracellular heat shock
protein 72 (eHSP72) increases during exercise-heat stress [65]. It has
been proposed that these chaperones contribute to proteome stabi-
lity in the biological ﬂuids by capturing and leading unfolded or
misfolded proteins for lysosomal proteolysis via endocytosis [66]. In
relation to proteostasis regulation, haptoglobin was shown to act as a
potential extracellular chaperone for β2-microglobulin in acidic
conditions during inﬂammation [67], while it also contributes to
hemoglobin (Hb) structural stabilization and possibly exerts an anti-
oxidative function during peroxidative stress [68]. α(2)M also reacts
with proteases and following its activation it inhibits amorphous and
ﬁbrillar protein aggregation [69]. CLU is a heterodimeric secreted
glycoprotein which is ubiquitously expressed in human tissues and
seems to exert its sHSPs-like chaperone function both extracellularly
as well as at intracellular compartments [70,71]. It is thus not
surprising that CLU has been functionally involved in many physio-
logical processes including ageing, as well as several age-related
diseases such as neurodegeneration, metabolic diseases and cancer
[72]. Although unrelated in their etiology and clinical manifestation,
all of these diseases represent states of increased oxidative stress,
which in turn, promotes increased genomic instability, amorphous
aggregation of target proteins and high rates of cellular death. Based
on this realization and the combined presence of many potential
regulatory elements in the CLU gene promoter, including a Heat
Shock transcription Factor-1 (HSF1) and an Activator Protein-1 (AP-1)
element, we recently proposed that the CLU gene is an extremely
sensitive cellular biosensor of even minute alterations in the cellular
oxidative load [72,73].
3. Redox biology and chaperones
Free radicals may have opposing effects in organisms' homeostasis
as in physiological levels they are essential for cell signalling whereas
at abnormally high levels they affect a wide variety of cellular
processes.
3.1. Sources of oxidants and cellular responses
The most important redox reaction in cells is the respiratory
chain that takes place in the mitochondrion, where electron
transport chain and oxidative phosphorylation are coupled to
synthesize ATP. Most of ROS are generated as undesirable side
products during the process where nicotinamide adenine dinu-
cleotide (NADH) or succinate delivers electrons to the respiratory
chain and the four complexes transfer electrons to ﬁnally reduce
O2 by forming water [1,2,74]. Excessive amounts of ROS may also
arise from inﬂammatory processes [75], excessive stimulation of
NAD(P)H oxidases [76], P450 metabolism and activity of peroxi-
somes [1,2,74]. Also, a number of exogenous sources facilitate the
production of free radicals including UV light, gamma rays, X-rays,
atmospheric pollutants, smoke and metal catalyzed reactions
[1,2,74]. As mentioned, at physiological cellular levels ROS act as
secondary messengers or signalling molecules and are essential in
intracellular signalling. Speciﬁcally, ROS have been shown to
regulate a wide variety of signalling pathways including anti-
inﬂammatory responses and adaptation to hypoxia [77,78], autop-
hagy [79], immune cell function [80], cellular differentiation [81],
integrins [82], as well as oncogenes signalling [83]. Thus, a very
delicate balance between free radicals production and removal or
neutralization occurs that confers cellular homeostasis.
An increase of intracellular or extracellular concentration of
ROS results in deregulation of redox-sensitive signalling pathways
and a series of primary and secondary responses begins in order to
re-establish the former balance. Primary cellular defensive
mechanisms include enzymes like the superoxide dismutases,
SOD1 (Cu–Zn SOD) and SOD2 (MnSOD) that convert superoxide
to H2O2 and catalase or glutathione peroxidase that convert H2O2
to H2O; additional non-enzymatic antioxidant defences are vita-
mins, carotenoids, thiol antioxidants and natural ﬂavonoids [3,5,7].
A main secondary antioxidant and cellular detoxiﬁcation program
is also executed by the NF-E2-related factor 2 (Nrf2)-Kelch-like
ECH-associated protein 1 (Keap1) signalling pathway. Under
normal conditions, Nrf2 is retained in the cytoplasm by the
actin-binding protein Keap1; a substrate adaptor protein for the
Cullin3-containing E3-ligase complex, which targets Nrf2 for
ubiquitination and degradation by the proteasome [84,85]. Keap1
is redox sensitive as its 27 cysteine residues act as sensitive
sensors of oxidative stress since they can be modiﬁed by different
oxidants and electrophiles [86]. Oxidative stress abrogates the
Keap1-mediated degradation of Nrf2 which in turn accumulates in
the nucleus where it heterodimerizes with a small musculoapo-
neurotic ﬁbrosarcoma (Maf) protein on antioxidant response
elements (AREs) to stimulate the expression of a wide arrays of
phase II and antioxidant enzymes including NAD(P)H quinone
oxidoreductase 1 (Nqo1), heme oxygenase 1 (Hmox1), glutamane-
cysteine ligase (GCL) and glutathione S transferases (GSTs)
[84,85,87,88]. Moreover, Nrf2 contributes to cellular proteostasis
by regulating the expression of molecular chaperones [89], as well
as of additional players of proteome stability and maintenance,
namely the proteasome subunits [90–92].
3.2. Impact of oxidative stress to cellular proteostasis and
chaperones activity
In those cases where the amount of oxygen free radicals exceeds
the antioxidant capacity of the cell, due to reduced levels of
antioxidants or malfunctioning antioxidant pathways, imbalance
between ROS generation and detoxiﬁcation occurs and risky oxida-
tive stress arise. Accumulating free radicals can then be harmful in
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cells by introducing stochastic damage to most cellular biomole-
cules including lipids, nucleic acids and proteins [3,7,93].
Protein oxidation results in reversible or irreversible protein
modiﬁcations affecting their secondary or tertiary structure and thus
their activity, solubility and stability [7,9,94]. Proteome oxidation and
instability has been associated with ageing and the progression of
several age-related diseases, including cardiovascular disorders, neu-
rodegeneration, and cancer [7,95,96]. ROS can modify proteins by
either affecting protein amino acids, especially cysteine residues, or by
modifying non-protein components such as lipids, which can then
react with amino- and thiol-groups of proteins [96–98]. Free radicals
can directly modify histidine residues to generate unstable amino
acids while cysteine and methionine residues can be converted to
disulﬁdes and methionine sulfoxide residues, respectively. A frequent
oxidative modiﬁcation of proteins is irreversible carbonylation which
can occur by either direct oxidation where oxidants act and leave a
functional carbonyl group on amino acid side chains or in the protein
backbone, or, indirectly, by protein conjugation with oxidation pro-
ducts of polyunsaturated fatty acids and carbohydrates [98]. Under
conditions of reduced antioxidant capacity superoxide anion can be
readily converted to hydroxyl radicals via Fenton chemistry. These
molecules are responsible for the production of lipid aldehydes, such
as 4-hydroxy trans-2,3-nonenal (4-HNE) and 4-oxo trans-2,3-nonenal
(4-ONE), which can react with various amino acids enabling protein
carbonylation [9,98–100]. Heavily carbonylated proteins tend to form
aggregates that are resistant to degradation and accumulate as
unfolded or damaged proteins [101]. These protein aggregates pro-
mote global proteome instability as they (among others) disrupt
the functionality of proteolytic pathways [102,103]. Large insoluble
aggregates, amyloids and partially denatured proteins activate the
HSP70 system to disassemble the protein skein. HSP70 proteins bind
their substrates and protein aggregates with low afﬁnity when they
are in the ATP-bound state, whereas the ADP-bound state has high
afﬁnity for its substrates (see also above); HSP70 function is assisted by
co-chaperones like HSP40 or HSP110 [104,105]. Interestingly, HSP70
was recently reported to also mediate dissociation and reassociation of
the 26S proteasome during adaptation to oxidative stress [106]; these
studies further highlight its crucial role in proteome stability and PDR.
As molecular chaperones activity is central to PN functionality
and proteome stability it is not surprising that they are tightly
regulated at both the transcriptional and post-translational level
under conditions of increased oxidative and, consequently, proteo-
toxic stress. Speciﬁcally, the expression of chaperone genes is
mainly regulated by a small group of transcription factors named
heat-shock factors (HSFs). Among the four HSFs that have been
identiﬁed in mammals, HSF1 is the dominant highly conserved
transcription factor [107]. HSF1 binds to a consensus heat shock
element (HSE) within the promoter regions of HSP genes resulting
in the activation of HSPs' gene expression and the control of cellular
responses to oxidative and proteotoxic stress [108]. As in the case of
Nrf2, the activation of HSF1 during stress is a multi-step process.
Speciﬁcally, under normal conditions HSF1 molecules remain in an
inert state as inactive monomers by being bound to various
chaperones/co-chaperones including HSP90, HSP70, HSP40 and
others [109] (Fig. 3). During elevated stress the chaperones within
the repressive HSF1-containing multi-chaperone complexes bind
the unfolded proteins and thus the liberated monomeric HSF1s
undergo phosphorylation, trimerization and nuclear localization
Fig. 3. Free radicals (e.g. ROS or RNS) are derived from exogenous (e.g. environmental) as well as intracellular (e.g. mitochondria, NOS, NOx) sources and at physiological
concentrations play a signiﬁcant role as regulatory mediators in signalling pathways. Under these conditions of minimal proteotoxic stress, chaperones (CHAP) are expressed
at basal levels and HSF1 is at an inert state by binding to chaperones (e.g. HSP90). A sustained increase in ROS beyond a physiological threshold (redox imbalance) results in
increased oxidative and proteotoxic stress. Consequently, HSF1 liberates from HSP90 (which now preferentially binds stressed proteins) and translocates to the nucleus to
enhance the expression levels of chaperone genes (transcriptional regulation; ❶). Also, chaperones can be activated at a post-translational level by cycling between a low-
and high-afﬁnity substrate binding state, depending on the redox state of their cysteines (❷). Chaperone bound extra- or intra-cellular stressed polypeptides can be either
refolded into their native form (n) or targeted to proteases for degradation (nn); similarly, accumulating protein aggregates can be disaggregated to unfolded intermediates
and either refolded or targeted for degradation.
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with increased transcriptional activity [109]. HSF1 is subject to
additional enzymatic post-translational modiﬁcations including
sumoylation [110] as well as acetylation [111], while at the post-
translational level of redox regulation, HSF1 can also sense oxidative
stress via two cysteine residues within the HSF1's DNA-binding
domain that are engaged in redox-sensitive disulﬁde bonds [112].
Cysteine residues are the most redox-sensitive side chains of
amino acids functioning as redox switches in proteins since they
are the ﬁrst amino acids that are oxidized under conditions of
increased oxidative stress; thus they are actively involved in post-
translational regulatory processes of redox imbalance responses [113].
Reversible thiol oxidation reactions that reportedly play a role in
redox regulation of proteins include the formation of intra- or
intermolecular disulﬁde bonds (R–S–S–R), stable sulfenic acid
intermediates (R-SOH), mixed disulﬁdes with the small tripeptide
glutathione (R–S–S–G) and the over-oxidation of cysteine thiols to
sulﬁnic acid (R–SO2H) [114]. Thus, proteins with redox-sensitive
amino acid side chains (such as Keap1 or HSF1) are used as sensors
of cellular oxidation status.
In the case of chaperones, the abundant ER molecular chaper-
one PDI is a critical player in oxidative folding of ER and extra-
cellular proteins. PDI is a redox sensitive chaperone that acts not
only as a sensor but also as a protein involved in the processing of
oxidized proteins and in preventing misfolding and/or aggregation
of proteins. PDI binds to oxidized proteins through their exposed
hydrophobic or aromatic residues and its folding activity is
stimulated by disulﬁde bonds created at proper sites [115].
Although it was controversial whether the chaperone activity of
PDI is redox-regulated it was shown recently that both the
chaperone activity and the overall conformation of human PDI
are redox-regulated via conformational changes that release the
compact conformation of the molecule and expose the shielded
hydrophobic areas to facilitate its high chaperone activity [116]. In
support, exposure of human cells to cigarette smoke affected the
formation of disulﬁde bonds through excessive posttranslational
oxidation of PDI resulting in increased amounts of complexes
between PDI and its client proteins [117]. Moreover, H2O2 oxidizes
Cys57 of Glutathione Peroxidase 7 (GPx7) to sulfenic acid, which
can be resolved by Cys86 to form an intramolecular disulﬁde bond.
Both the disulﬁde form and sulfenic acid form of GPx7 can oxidize
PDI for catalyzing oxidative folding [118]. Another member of the
GPx family, namely NPGPx transmits oxidative stress signals by
forming the disulﬁde bond between its Cys57 and Cys86 residues.
This oxidized form of NPGPx binds to GRP78 and forms covalent
bonding intermediates between Cys86 of NPGPx and Cys41/
Cys420 of GRP78; subsequently, the formation of the disulﬁde
bond between Cys41 and Cys420 of GRP78 enhances its chaperone
activity [119].
Additional paradigms of post-translational redox-mediated
modiﬁcations that guarantee an immediate response to oxidative
stress conditions refer to the Hsp33 chaperone in bacteria as well
as to typical 2-Cys peroxiredoxins in eukaryotes [120]. In the case
of Hsp33, oxidative stress-mediated disulﬁde bond formation
triggers a partial unfolding of the chaperone, which leads to the
exposure of a high-afﬁnity binding site for unfolded proteins and
thus the protein becomes a highly efﬁcient holdase that binds
tightly to unfolding proteins [121]. This rapid conformational
change inhibits bacterial functional amyloid assembly [122] and
it protects bacteria cells from hypochlorite (bleach) treatment-
mediated proteotoxic stress [123,124]. Regarding the highly abun-
dant eukaryotic typical 2-Cys peroxiredoxins (which are found in
various subcellular compartments) the oxidative stress-mediated
formation of sulﬁnic acid turns the peroxidase into a molecular
chaperone [125]. During this process a catalytically active cysteine
attacks the O–O bond of the ROOH substrate, thereby forming the
ROH product and a sulfenic acid (CP-SOH) on the catalytically
active cysteine [126]. The mechanism of active cysteine regenera-
tion (which is different among the individual members of the
peroxiredoxin family) involves the attack of CP-SOH by a free thiol
and the release of water [127]. Additional studies in mammalian
peroxiredoxins showed that over-oxidation induces the formation
of high molecular weight oligomers which function as potent
chaperones and prevent protein aggregation [128,129]; these
ﬁndings indicate that typical 2-Cys peroxiredoxins might act as
the eukaryotic counterpart of bacterial Hsp33 by using a unique
“sulﬁnic acid switch” to convert from a peroxidase under non-
stress conditions to a molecular chaperone under severe oxidative
stress conditions [128].
These observations highlight the dual role of chaperones in PN
stability as both proteome caretakers, as well as sensors of
disrupted cellular redox homeodynamics.
4. Conclusive remarks
A large body of evidence supports the direct implication of
abnormally high levels of free radicals in the progression and
pathogenesis of several unrelated diseases. Central to the progression
of these diseases is the free radicals-mediated induction of proteome
instability that is accompanied by deregulation of the PN modules.
This realization is in line with reports showing constant activation of
the Nrf2 antioxidant program and high expression levels of chaper-
ones in advanced tumors as well as in degenerative diseases [7].
In fact this process refers to global systemic alterations that even-
tually enable abnormal (e.g. cancer) cells to exploit PN as a mean to
suppress proteotoxic stress and to shape the ultimate landscape for
the progression of the disease. The comprehension of this process
offers novel therapeutic opportunities, as it seems that in some cases
diseased cells have exhausted their capacity to survive under condi-
tions of increased oxidative and proteotoxic stress. In support, it was
recently showed that a novel compound (piperlongumine) increased
ROS in both cancer and normal cells but it had selective in vivo anti-
tumor effects with no apparent toxicity in normal mice [130].
Moreover, a plethora of HSP90 inhibitors are currently investigated
in clinical or preclinical trials as anti-tumor drugs [131–134]; 17-AAG,
an HSP90 inhibitor, ameliorates polyglutamine-mediated motor
neuron degeneration [135], while an antisense oligonucleotide that
targets CLU gene expression is currently in advanced clinical trials for
several types of cancer [136]. Furthermore, a GRP78/BiP-targeting
cytotoxin treatment along with photodynamic therapy eliminates
lung cancer cell lines [137] and this chaperone is also under
investigation for the treatment of neurodegenerative diseases
[138,139]. Additionally, the enhancement of HSF1 activity or chaper-
ones expression by genetic techniques or pharmacological manip-
ulation has been shown to restore proteostasis in several models of
degenerative diseases or to delay ageing [140–142]. In conclusion
proteome stability is a key determinant of cellular homeostasis in the
healthy organism and thus the expansion of our current knowledge
on PN regulation and PDR will also provoke innovative new
strategies for the treatment of human diseases.
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